COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Uğur Şahin(Johannes Gutenberg University Mainz), Alexander Muik(BioNTech (Germany)), Evelyna Derhovanessian(BioNTech (Germany)), Isabel Vogler(BioNTech (Germany)), Lena M. Kranz(BioNTech (Germany)), Mathias Vormehr(BioNTech (Germany)), Alina Baum(Regeneron (United States)), Kristen E. Pascal(Regeneron (United States)), Jasmin Quandt(BioNTech (Germany)), Daniel Maurus(BioNTech (Germany)), Sebastian Brachtendorf(BioNTech (Germany)), Verena Lörks(BioNTech (Germany)), Julian Sikorski(BioNTech (Germany)), Rolf Hilker(BioNTech (Germany)), Dirk Becker(BioNTech (Germany)), Ann-Kathrin Eller(BioNTech (Germany)), Jan Grützner(BioNTech (Germany)), Carsten Boesler(BioNTech (Germany)), Corinna Rosenbaum(BioNTech (Germany)), Marie-Cristine Kühnle(BioNTech (Germany)), Ulrich Luxemburger(BioNTech (Germany)), Alexandra Kemmer-Brück(BioNTech (Germany)), David Langer(BioNTech (Germany)), Martin Bexon(Bexon Clinical Consulting (United States)), Stefanie Bolte(BioNTech (Germany)), Katalin Karikó(BioNTech (Germany)), Tania Palanche(BioNTech (Germany)), Boris Fischer(BioNTech (Germany)), Armin Schultz(Clinical Research Services), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Camila R. Fontes-Garfias(The University of Texas Medical Branch at Galveston), John L. Perez(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), Jakob Loschko(Pfizer (United States)), Ingrid L. Scully(Pfizer (United States)), Mark Cutler(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), Christos A. Kyratsous(Regeneron (United States)), David Cooper(Pfizer (United States)), Philip R. Dormitzer(Pfizer (United States)), Kathrin U. Jansen(Pfizer (United States)), Özlem Türeci(BioNTech (Germany))
Cited by 2,042Open Access